X4 Pharmaceuticals Stock Today
| XFOR Stock | USD 0.30 0.0008 0.27% |
PerformanceVery Weak
| Odds Of DistressVery High
|
X4 Pharmaceuticals is selling at 0.3008 as of the 20th of March 2025; that is 0.27 percent increase since the beginning of the trading day. The stock's lowest day price was 0.29. X4 Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2017 | Category Healthcare | Classification Health Care |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. The company was founded in 2010 and is headquartered in Boston, Massachusetts. The company has 170.55 M outstanding shares of which 11.06 M shares are at this time shorted by private and institutional investors with about 1.59 trading days to cover. More on X4 Pharmaceuticals
Moving together with XFOR Stock
Moving against XFOR Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
XFOR Stock Highlights
| CEO | Paula Ragan | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsX4 Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand X4 Pharmaceuticals' financial leverage. It provides some insight into what part of X4 Pharmaceuticals' total assets is financed by creditors.
| |||||
X4 Pharmaceuticals (XFOR) is traded on NASDAQ Exchange in USA. It is located in 61 North Beacon Street, Boston, MA, United States, 02134 and employs 143 people. X4 Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 51.1 M. X4 Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 170.55 M outstanding shares of which 11.06 M shares are at this time shorted by private and institutional investors with about 1.59 trading days to cover.
X4 Pharmaceuticals currently holds about 47.38 M in cash with (96.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check X4 Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationX4 Pharmaceuticals secures a total of 170.55 Million outstanding shares. Over half of X4 Pharmaceuticals' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check XFOR Ownership Details
XFOR Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Pale Fire Capital Se | 2024-12-31 | 1.4 M | |
| Schonfeld Strategic Advisors Llc | 2024-12-31 | 1.4 M | |
| Northern Trust Corp | 2024-12-31 | 1.4 M | |
| Gsa Capital Partners Llp | 2024-12-31 | 1.3 M | |
| Ubs O'connor Llc | 2024-12-31 | 1.3 M | |
| Ubs Group Ag | 2024-12-31 | 923.1 K | |
| Group One Trading, Lp | 2024-12-31 | 797.4 K | |
| Point72 Asset Management, L.p. | 2024-12-31 | 650 K | |
| Jane Street Group Llc | 2024-12-31 | 583.5 K | |
| Bain Capital Life Sciences Investors, Llc | 2024-12-31 | 16.9 M | |
| Nea Management Company, Llc | 2024-12-31 | 15 M |
X4 Pharmaceuticals Historical Income Statement
XFOR Stock Against Markets
X4 Pharmaceuticals Corporate Management
| Robert Arbeit | Senior Research | Profile | |
| Mary DiBiase | Chief Officer | Profile | |
| Keith MD | Founder Board | Profile | |
| Pharm MPH | Vice Communications | Profile | |
| Renato Skerlj | Founder | Profile |
Already Invested in X4 Pharmaceuticals?
The danger of trading X4 Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of X4 Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than X4 Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile X4 Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.